Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reissued by equities research analysts at Royal Bank Of Canada in a research report issued on Wednesday. They currently have a $117.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would indicate a potential upside of 84.78% from the stock’s previous close.

Several other research analysts have also recently weighed in on the company. J P Morgan Chase & Co decreased their price target on Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating for the company in a research note on Tuesday, September 12th. Leerink Swann restated an “outperform” rating and issued a $97.00 price target (up previously from $90.00) on shares of Sage Therapeutics in a research note on Tuesday, June 20th. Stifel Nicolaus restated a “buy” rating and issued a $90.00 price target on shares of Sage Therapeutics in a research note on Friday, July 14th. Canaccord Genuity decreased their price target on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating for the company in a research note on Tuesday, September 12th. Finally, BidaskClub cut Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 28th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Sage Therapeutics presently has an average rating of “Buy” and an average price target of $86.79.

Sage Therapeutics (NASDAQ:SAGE) traded down 1.224% during midday trading on Wednesday, reaching $62.545. The company had a trading volume of 67,014 shares. The company has a 50-day moving average of $69.94 and a 200-day moving average of $74.43. The stock’s market capitalization is $2.34 billion. Sage Therapeutics has a 12-month low of $38.30 and a 12-month high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period in the previous year, the firm posted ($1.08) earnings per share. On average, analysts predict that Sage Therapeutics will post ($7.40) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Royal Bank Of Canada Reaffirms “Buy” Rating for Sage Therapeutics, Inc. (SAGE)” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://theolympiareport.com/2017/10/18/royal-bank-of-canada-reaffirms-buy-rating-for-sage-therapeutics-inc-sage.html.

A number of large investors have recently added to or reduced their stakes in SAGE. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 138 shares during the period. Turner Investments LLC bought a new stake in Sage Therapeutics during the second quarter valued at about $159,000. Dubuque Bank & Trust Co. bought a new stake in Sage Therapeutics during the second quarter valued at about $167,000. Canada Pension Plan Investment Board bought a new stake in Sage Therapeutics during the second quarter valued at about $175,000. Finally, Teacher Retirement System of Texas bought a new stake in Sage Therapeutics during the second quarter valued at about $202,000.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.